Moawia Mohammed Ali Elhassan, Associate Professor at University of Gezira, Consultant of Clinical and Radiation Oncology at Universal Hospital Sudan, shared a post on LinkedIn about a recent article by Deirdre J. Cohen et al, published in The Oncologist Journal:
“Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma
A recent multi-institutional Phase II study in The Oncologist Journal assessed the safety and efficacy of peri-operative chemotherapy and pre-operative SBRT in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
This trial investigated a specific perioperative regimen included three cycles of GEM/NAB prior to SBRT (6.6 Gy daily × 5) followed by surgery and three cycles of adjuvant GEM/NAB in both Resectable PDAC and Borderline Resectable PDAC cohorts.
Despite combining systemic therapy with SBRT, overall R0 rates and survival outcomes were lower than hoped for in both groups.”
Title: Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study
Authors: Deirdre J. Cohen, Judith D. Goldberg, Lawrence Leichman, Tsivia Hochman, Elliot Newman, Kevin Du, Alec Megibow, Paul Oberstein, Raed Al-Rajabi, Aaron J. Scott, Tanios Bekaii-Saab, Wells A. Messersmith, Colin Weekes
Read the Full Article on The Oncologist Journal
More posts featuring Moawia Mohammed Ali Elhassan.